Windsor Framework Medicines ProvisionsWindsor Framework Medicines — Single UK Marketing Authorisation and UK Only Packaging
From 1 January 2025 the Windsor Framework replaced the Northern Ireland Protocol's medicines arrangements: the MHRA now licenses human medicines on a UK-wide basis, EU Falsified Medicines Directive safety features no longer apply anywhere in the UK, and packs placed on the UK market must carry a 'UK Only' label.

On this page · 8 sections
- 1The pre-2025 position: the NI Protocol and EU medicines law in Northern Ireland
- 2The Windsor Framework agreement and its medicines timeline
- 3UK-wide licensing by the MHRA
- 4The EMA's role for Northern Ireland medicines ends
- 5Removal of EU FMD safety features and batch testing changes
- 6The 'UK Only' labelling and packaging requirement
- 7What still differs: pharmacovigilance, parallel imports and goods-wide EU law
- 8Practical steps for manufacturers: packaging changeovers and label version control
How does Windsor Framework Medicines Provisions apply to your shop floor?
Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.
01The pre-2025 position: the NI Protocol and EU medicines law in Northern Ireland
Before 1 January 2025, the Northern Ireland Protocol kept Northern Ireland inside the EU's regulatory orbit for medicines even though the rest of the UK had left. Novel medicines that fell within the mandatory or optional scope of the EU's Centralised Procedure were approved for Northern Ireland by the European Medicines Agency (EMA) and the European Commission, under a 'union authorisation' valid across the EU, while the same products needed a separate Great Britain-only marketing authorisation (a 'PLGB') from the MHRA to be sold in England, Scotland and Wales. A manufacturer selling UK-wide therefore often held two licences, on two legal bases, for what was functionally one product.
That split licensing carried through into packaging. Because Northern Ireland packs had to satisfy EU rules, including the EU's Falsified Medicines Directive (FMD) safety-features requirement — a unique 2D barcode and an anti-tampering device, verified against an EU verification system and decommissioned at the point of dispensing — while Great Britain packs did not (FMD ceased to apply in Great Britain from the end of the Brexit transition period on 31 December 2020), manufacturers who wanted a single UK-wide pack design faced a structural mismatch: either run two pack designs, or build every UK pack to the stricter Northern Ireland/EU specification.
The UK and EU had agreed a temporary derogation in April 2022 allowing medicines to continue moving through Great Britain without full FMD verification and decommissioning, but that derogation was due to lapse at the end of 2024. Left unresolved, the MHRA's own explainer guidance states that this would have applied the full FMD packaging, barcoding and scanning requirement in Northern Ireland from 1 January 2025, with a real risk that companies would judge it uneconomic to maintain a separate Northern Ireland-compliant pack and decide not to supply Northern Ireland at all — the supply-continuity problem the Windsor Framework was built to solve.
02The Windsor Framework agreement and its medicines timeline
The UK and the EU announced the Windsor Framework on 27 February 2023, replacing the original Northern Ireland Protocol with a new set of arrangements. For medicines specifically, the MHRA announced on 9 June 2023 that the human medicines measures agreed under the Framework would commence on 1 January 2025, giving industry roughly eighteen months to prepare licensing, labelling and quality-system changes. The underlying UK legislation implementing these changes is the Human Medicines (Amendments relating to the Windsor Framework) Regulations 2024, which amends the Human Medicines Regulations 2012.
The MHRA's own framing of the change is that it brings novel medicines — the ones that would previously have needed the EU Centralised Procedure — under UK law and UK licensing, so that 'the same medicines are available at the same time, in the same packs and on the same legal and regulatory basis right across the UK.' Three changes sit at the centre of the 1 January 2025 package: UK-wide licensing by the MHRA, disapplication of the EU FMD safety-features requirement across the whole UK, and a mandatory 'UK Only' label on packs placed on the UK market.
MHRA guidance also set a one-year deadline extension for packaging changeovers: manufacturers had previously faced a 31 December 2023 deadline to move Great Britain packs onto GB-compliant packaging, and the Windsor Framework package pushed the single deadline for the new UK-wide packaging requirements out to 31 December 2024, with the MHRA continuing to allow supply of medicines in legacy EU-compliant packaging until that date and allowing existing stock already in the supply chain to be sold through to its labelled expiry date.
03UK-wide licensing by the MHRA
From 1 January 2025 the MHRA licenses human medicines across the whole of the UK, and union authorisations issued by the European Commission are no longer valid for Northern Ireland; the MHRA instead issues UK-wide authorisations covering what were previously centrally authorised products (CAPs). MHRA guidance introduces two new classifications that every UK-wide marketing authorisation (MA) is assigned to: Category 1 covers medicines that previously fell within the mandatory or optional scope of the EU Centralised Procedure (broadly, the rules that applied to the old GB-only 'PLGB' licences carry across to this category), while Category 2 covers medicines that do not fall within that scope (broadly mirroring the rules that already applied to UK-wide 'PL' licences).
Existing GB-only marketing authorisations (PLGBs) converted automatically to UK-wide authorisations on 1 January 2025 unless the holder or the MHRA cancelled them beforehand, and they kept their existing MA number, including the 'PLGB' prefix, even though the prefix no longer reflects a GB-only territorial scope. A marketing authorisation holder cannot simultaneously hold a UK-wide MA and a Northern Ireland-only MA (PLNI) for the same product: MAHs who wanted UK-wide coverage and had been holding both a PLNI and a PLGB needed to request cancellation of the PLNI by 30 September 2024 so the PLGB could convert automatically. From 1 January 2025 the MHRA no longer accepts new applications for GB-only MAs at all — it retains the right to issue one only in exceptional circumstances to safeguard patients' health, not as a routine application route.
04The EMA's role for Northern Ireland medicines ends
Before the Windsor Framework, the EMA and European Commission were the licensing authority for medicines that fell within the EU Centralised Procedure's scope when those medicines were to be supplied in Northern Ireland — a role the EMA no longer has from 1 January 2025. The MHRA explainer states plainly that, from that date, union authorisations issued by the European Commission are no longer valid for Northern Ireland, and the MHRA issues the UK-wide authorisation in their place.
Until 31 December 2024 inclusive, the EU remained responsible for authorising medicines in Northern Ireland that fell under the mandatory scope of the Centralised Procedure (mostly new and innovative products), and generic, hybrid or biosimilar applications referencing those products had to cite the centrally authorised product as the reference product up to that date. From 1 January 2025 that reference-product logic shifts onto a UK footing: generally only reference products authorised for at least eight years in the UK (or in GB before 1 January 2025) support a generic, hybrid or biosimilar application, and Category 1 products authorised directly by the MHRA (including converted former-CAP authorisations) can themselves now be cited as reference products for later UK-wide applications.
05Removal of EU FMD safety features and batch testing changes
The EU FMD safety-features requirement — verification of a pack's unique 2D barcode and an anti-tampering device, checked against the EU's verification system — no longer applies anywhere in the UK, including Northern Ireland, from 1 January 2025. MHRA guidance confirms the FMD system was disapplied UK-wide from midnight on 31 December 2024 and that the UK national repository (the UK National Medicines Verification System, NMVS) is no longer accessible. For products supplied in the UK from 1 January 2025, any safety feature that was added to comply with FMD — specifically, any barcode recognisable by the EU verification system — must be removed or covered. Marketing authorisation holders may still choose, on a voluntary basis, to apply a 2D Data Matrix barcode or a serial number of any format, but neither is compulsory, and the MHRA continues to encourage (without mandating) the retention of anti-tamper packaging features generally.
A related but separate change affects batch release testing for biological medicines. Before 1 January 2025, Northern Ireland could rely on EU Official Control Authority Batch Release (OCABR) certification in addition to certification by the MHRA's National Institute for Biological Standards and Control (NIBSC); Great Britain relied on NIBSC alone. From 1 January 2025, because biological medicines in Category 1 are licensed UK-wide under UK law, NIBSC certifies biologicals on a UK-wide basis and all batches for sale or supply in the UK generally require NIBSC certification, subject to narrow exceptions for batches certified in a country with a mutual recognition agreement with the UK (currently Switzerland and Israel). EU OCABR certificates issued after 31 December 2024 are no longer automatically accepted for Northern Ireland batches, though evidence of a previously obtained OCABR certificate may still be considered by the MHRA — manufacturers with products affected by this change are directed to MHRA's ControlTesting mailbox to discuss specific arrangements.
06The 'UK Only' labelling and packaging requirement
All licensed medicines placed on the UK market and QP-certified on or after 1 January 2025 must carry the wording 'UK Only' on the outer packaging, regardless of legal classification — prescription-only medicines, pharmacy medicines and general sales list medicines are all in scope. The purpose, as MHRA guidance states directly, is to prevent onward movement of UK medicines into the EU single market, since those products are no longer dual-authorised under an EU procedure.
The requirement follows Article 5 of EU Regulation 2023/1182 (the instrument underpinning the Windsor Framework's medicines arrangements) and sets several conditions: 'UK Only' may be placed anywhere on the outer packaging provided it is in a conspicuous position, easily visible, and not hidden, obscured, detracted from, or interrupted by other written or pictorial matter; it must be clearly legible and indelible, in a font size of at least 7; and larger packs must still position the wording so it remains easily visible and clearly legible at that scale. As a transitional easement, stickers may be used to apply the 'UK Only' wording, but only for a limited window — until 30 June 2025 — after which printed artwork is expected to carry the wording directly.
Stock that was already QP-certified in the relevant territory (Great Britain or Northern Ireland) before 1 January 2025, in its pre-existing packaging, can continue to be supplied to patients in that territory until the medicine's labelled expiry date — manufacturers are not required to recall or relabel compliant stock already in the supply chain. Traditional herbal registrations (THR) and homeopathic registrations (HR) fall outside the scope of the Windsor Framework and are not obliged to carry the 'UK Only' label, though MHRA guidance notes companies may still choose to apply it.
07What still differs: pharmacovigilance, parallel imports and goods-wide EU law
The Windsor Framework did not remove every Northern Ireland-specific feature of medicines regulation. MHRA guidance is explicit that 'some areas of EU law continue to apply for medicines, reflecting the fact that Northern Ireland retains access to the EU single market.' Pharmacovigilance requirements differ by category rather than by territory from 1 January 2025: Category 1 products follow Part 11 of the Human Medicines Regulations together with Schedule 12A2, while Category 2 products follow Part 11 together with the EU's Commission Implementing Regulation (EU) No. 520/2012 — meaning a product that is now licensed UK-wide can still carry EU-derived pharmacovigilance obligations depending on its category, and a marketing authorisation holder should check both the category assignment and the applicable pharmacovigilance guidance rather than assuming UK-wide licensing means UK-only obligations throughout.
Parallel import arrangements were also restructured rather than eliminated. Before 1 January 2025, centrally authorised products reaching the UK through parallel import needed a UK parallel import licence (PLPI) valid for Great Britain only, plus a separate EMA parallel distribution notice for Northern Ireland; from 1 January 2025, PLPIs for centrally authorised products can be authorised UK-wide, and existing GB-limited PLPIs converted automatically to UK-wide authorisation, subject to the same 'UK Only' labelling requirements as other UK-market medicines.
Beyond medicines specifically, the Windsor Framework sits within a broader settlement in which Northern Ireland continues to apply EU rules for goods generally, and customs arrangements for goods moving between Great Britain and Northern Ireland operate under the Framework's separate green-lane/red-lane structure. This article does not cover those goods-wide customs mechanisms in detail; readers needing the customs position for a specific product should consult the dedicated HMRC and Windsor Framework guidance on moving goods into Northern Ireland.
08Practical steps for manufacturers: packaging changeovers and label version control
MHRA's wholesaler and manufacturer guidance frames the transition as something that needed active preparation well before the 1 January 2025 go-live, not a change that happened automatically to existing stock. Marketing authorisation holders were told to submit updated labelling artwork to the MHRA as early as possible, and where the self-certification submission route applies, a company did not need to wait for MHRA approval before implementing the proposed change once it had submitted the updated artwork — meaning the practical constraint for many manufacturers was internal: getting artwork, print specifications and quality sign-off aligned to the new wording and FMD-feature removal in time.
A manufacturer running GB and former-EU-compliant Northern Ireland pack designs in parallel through the transition period needed to manage at least three live artwork states at once: legacy EU-compliant Northern Ireland packaging (sellable until expiry even after go-live), legacy GB packaging without 'UK Only' wording (also sellable until expiry), and new UK-wide packaging carrying the 'UK Only' label with FMD features removed or covered. Robust label version control — a controlled artwork master, a clear effective-date and change-control record for each version, and a release mechanism that prevents an obsolete version reaching the line after its retirement date — is the practical safeguard against a batch going out under withdrawn artwork, particularly given the sticker-based 'UK Only' route was only permitted until 30 June 2025.
Dual inventory management followed directly from the packaging changes. Because PLGB packs could only be supplied to Northern Ireland from 1 January 2025 onward, and because stock in existing packaging could continue to be sold through to its labelled expiry in the territory it was certified for, warehouses needed inventory systems able to hold, and correctly route, at least two pack variants of the same product simultaneously for a period — rather than treating a pack-design change as a single cut-over date across all stock. MHRA guidance also removed one storage option during this period: from 1 January 2025 it is no longer possible to use EEA-located storage facilities to store 'UK Only' labelled medicines that have already been placed on the UK market, so manufacturers and wholesalers using EEA warehousing as part of a UK distribution chain needed to re-route that storage within the UK.
Frequently asked questions
Q.When did the Windsor Framework's medicines arrangements take effect?+
The human medicines measures agreed under the Windsor Framework commenced on 1 January 2025, as announced by the MHRA on 9 June 2023 and confirmed in subsequent MHRA guidance published through 2024 and early 2025. The Windsor Framework agreement itself was announced by the UK and EU on 27 February 2023, replacing the original Northern Ireland Protocol; the medicines provisions took eighteen months longer to come into force to give industry time to prepare.
Q.Does the EMA still license medicines for Northern Ireland?+
No. From 1 January 2025 union authorisations issued by the European Commission are no longer valid for Northern Ireland, and the MHRA issues UK-wide marketing authorisations in their place, including for products that were previously centrally authorised through the EMA's Centralised Procedure. Before that date, the EU remained responsible for authorising medicines in Northern Ireland that fell within the mandatory scope of the Centralised Procedure.
Q.Do all medicines on the UK market now need a 'UK Only' label?+
All licensed medicines placed on the UK market and QP-certified on or after 1 January 2025 must carry the 'UK Only' wording on their outer packaging, regardless of legal classification (prescription-only, pharmacy, or general sales list). Stock already QP-certified in its territory before that date can continue to be supplied until its labelled expiry without relabelling. Traditional herbal registration (THR) and homeopathic registration (HR) products fall outside the Windsor Framework's scope and are not obliged to carry the label.
Q.Does the EU Falsified Medicines Directive still apply anywhere in the UK?+
No. The FMD safety-features requirement was disapplied UK-wide from midnight on 31 December 2024, and the UK's national medicines verification repository is no longer accessible. Packs supplied in the UK from 1 January 2025 must have any EU-recognisable FMD barcode removed or covered. A marketing authorisation holder may still choose to apply a voluntary 2D barcode or serial number, and the MHRA continues to encourage anti-tamper packaging generally, but neither is a Windsor Framework legal requirement.
Q.Do veterinary medicines follow the same 1 January 2025 timetable as human medicines?+
No. Veterinary medicines are covered by a separate Windsor Framework arrangement with its own, later implementation date. Government guidance published 19 June 2025 confirms the Windsor Framework rules for veterinary medicines distribution in Northern Ireland apply in full from 1 January 2026, with dedicated Veterinary Medicines Directorate guidance covering marketing authorisation holders, wholesalers and retailers, and the Veterinary Medicines Internal Market Scheme. Anyone handling veterinary products should check current VMD guidance rather than apply the human-medicines dates.
Primary sources
- MHRA Windsor Framework hub (gov.uk) — reviewed 9 Oct 2026
- Windsor Framework agreement on the supply of medicines in Northern Ireland explained (gov.uk) — reviewed 9 Oct 2026
- UK-wide licensing for human medicines (gov.uk) — reviewed 9 Oct 2026
- UK-wide licensing for human medicines: supplementary guidance (gov.uk) — reviewed 9 Oct 2026
- Labelling and packaging of medicinal products for human use following agreement of the Windsor Framework (gov.uk) — reviewed 9 Oct 2026
- Wholesalers' and manufacturers' guidance following agreement of the Windsor Framework (gov.uk) — reviewed 9 Oct 2026
- Unfettered access procedure for marketing authorisations approved in Northern Ireland (gov.uk) — reviewed 9 Oct 2026
- Windsor Framework medicines announcement, 9 June 2023 (gov.uk) — reviewed 9 Oct 2026
- Protecting Animal Health: The Government's Approach to Veterinary Medicines in Northern Ireland (gov.uk, 19 June 2025) — reviewed 9 Oct 2026
- Supplying veterinary medicines to Northern Ireland (gov.uk, VMD) — reviewed 9 Oct 2026
Further reading
- MHRA Data Integrity GuidanceMHRA's broader GB/UK-wide inspection expectations, relevant background alongside the Windsor Framework licensing changes.
- Batch ReleaseThe QP certification and release step affected by the Windsor Framework's biological medicines batch-testing changes.
- CE MarkingRelated UK/EU post-Brexit dual-marking context for products moving between Great Britain and Northern Ireland.
- QA AuditHow a quality team verifies that labelling and artwork changes, such as the Windsor Framework's 'UK Only' requirement, were implemented correctly.
- Independent Part 11 AssessmentThird-party review of V5 Ultimate's electronic-record controls, relevant to the artwork and label version-control records this transition required.
- V5 Ultimate for Pharmaceutical — OverviewGeneral pharmaceutical manufacturing overview; does not describe Windsor Framework-specific regulatory functionality.
Want to see how Windsor Framework Medicines Provisions could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.
